Antiangiogenic drug to treat cancer, arthritis and retinopathy

US5932545A · kind A · utility

Assignee

• Abbott Laboratories · US

Inventors

• Jack Henkin · Highland Park, US
• Noel P. Bouck · Oak Park, US
• David W. Dawson · Los Angeles, US
• Andrew J. Schneider · Gurnee, US

Key dates

• Filing date: Mar 16, 1998
• Grant date: Aug 3, 1999
• Expiry date: Mar 16, 2018

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Peptides having the formula: EQU T-Gly-Val-D-Ile-Thr-Arg-Ile-U, EQU V-Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-W, EQU X-D-Arg-D-Ile-D-Arg-D-Thr-lle-D-Val-Y, and EQU Z-Gly-Val-Ile-Thr-Arg-Ile-U wherein T is absent or is selected from N-protecting group and a polypeptide of up to 12 amino acid residues optionally terminated with a N-protecting group; U is selected from Arg and Arg-NR.sup.1 R.sup.2 wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and alkyl of one to four carbon atoms; V is absent or a N-protecting group; W is selected from D-Arg and D-Arg-NR.sup.1 R.sup.2 ; X is absent or a N-protecting group; Y is selected from Gly and Gly-NR.sup.1 R.sup.2 ; and Z is 1-12 amino acid residues optionally terminated with a N-protecting group wherein at least one of the amino acid residues is a D-amino acid residue inhibit angiogenesis and are useful in the treatment of disease states such as cancer, arthritis, macular degeneration and diabetic retinopathyin which angiogenesis plays a role.